Eli Lilly Releases Sneak Peek of Trial Data for Alzheimer’s Drug Donanemab
By
Simon Spichak, MSc
| May 4th, 2023
After almost two decades of stagnation, two new drugs for Alzheimer’s have hit the market in the last three years. The approval of Biogen…